Redwire Wins NASA Contract to Launch Additional Drug Investigations in Space

MT Newswires Live03-25

Redwire (RDW) said Tuesday that it was awarded a NASA contract to launch four additional pharmaceutical drug investigations at the International Space Station using the company's pharmaceutical in-space laboratory.

Financial terms were not disclosed.

The NASA-funded investigations aim to manufacture protein-based and other molecular seed crystals which could provide insights and data for low-gravity pharmaceutical manufacturing operations aboard the space station and other commercial space stations in low Earth orbit, the company said.

The company said previous investigations suggest that growing crystals in space could yield a more uniform product with fewer imperfections, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment